Core Viewpoint - The company, Shuanglu Pharmaceutical, is expected to continue incurring losses in 2025, with a projected net profit loss of between -200 million to -290 million yuan, representing a significant increase in losses compared to the previous year [1][3]. Financial Performance - In 2024, Shuanglu Pharmaceutical reported an operating income of approximately 660 million yuan, a year-on-year decrease of 35.15%, and a net profit loss of about -74.07 million yuan, marking a shift from profit to loss [3]. - The projected net profit for 2025 is expected to decline by 170.03% to 291.54% compared to the previous year, with a forecasted non-recurring net profit loss of -40 million to -70 million yuan, a decrease of 148.58% to 185.02% year-on-year [3][4]. Sales and Margins - The company experienced a sales gross margin decline of approximately 10% due to a decrease in product prices, which was influenced by the implementation of centralized drug procurement policies [4][5]. - The sales revenue of the company's primary product line, anti-tumor and immune regulation products, fell by 27.69% in 2024, contributing to the overall revenue decline [5]. Investment Losses - Non-recurring losses, including confirmed investment losses and changes in fair value of financial assets, are expected to reduce net profit by approximately 200 million yuan in 2025 [6]. - The chairman, Xu Mingbo, has voluntarily committed to cover any irrecoverable investment losses, with an initial payment of 50 million yuan to the company [6]. Strategic Response - The company plans to accelerate the launch of new products and strengthen its marketing network to adapt to changes in the pharmaceutical market due to procurement policies [5]. - Shuanglu Pharmaceutical is also evaluating its investment losses and has made significant provisions for asset impairment to mitigate the impact on net profit [6].